by Raynovich Rod | Nov 12, 2019 | 2019 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Nice Gains for Biotech Today: AMRN DRNA CRSP SGEN Amarin (AMRN) one of our top small cap picks for 2019 soared 23.83% today on expectations that the FDA will recommend a broader indication for its fish-oil drug. Amarin wants to say in its Vascepa label that the...
by Raynovich Rod | Nov 10, 2019 | Biopharmaceuticals, Macro
Biotech and Healthcare Stocks Notch -Up with Bullish Tape Action Since we called the early October reversal for healthcare and biotech stocks we have seen great gains of 5-7% with more gains ahead assuming good clinical news and M&A. Friday we saw a good tape...
by Raynovich Rod | Nov 7, 2019 | Biopharmaceuticals, Macro
Biotech Action Today is Muddled-Midday Selloff presumably on “Recycling” of China Trade Chatter Uncertainty Remains on Trade War and Tariffs Little rally in gene therapy stocks; 1% + Winners include QURE RGNX SRPT; XBI up only 0.26% as rally faded. Mixed...
by Raynovich Rod | Nov 4, 2019 | Biopharmaceuticals
Update-1 11/5 2p EST IBB flat, NAZ up 0.185, earnings from AMRN and REGN. Amarin down 3.5% to $16.83 on earnings but bulls are waiting for label expansion. Q3 Revenues are $112.4 M up 103%, increased prescriptions for Vascepa with a 12/28/19 PADUFA date. Regeneron...
by Raynovich Rod | Oct 31, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 Genmark (GNMK) down 3.6 % to $5.61 on Q3 results. Beat on revenue to $20.9 M up 32 % over prior quarter, loss of 20 cents/share.Waiting for a buy-out in 2020? Update-1 …Nov. 1…All of these picks are up today, IWM is up 1.6%, IJR is up...
by Raynovich Rod | Oct 28, 2019 | 2009-2017 Life Science Portfolios, Biopharmaceuticals
Update 10/30 1:45 pm EDT Markets weak on China deal, PMI data Sold CRSP at $50.with 25% gain in 2 weeks; will get back in on weakness. XBI off 0.89%, IBB down 0.85%, NAZ off 0.44%. BMY up 1.5% near 52 week highs. Teledoc (TDOC) a top 2019 small cap pick up over 12% on...
by Raynovich Rod | Oct 23, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/25 at close…A Good Day on Low Volume-NASDAQ up 0.7%, S&P is up 20.56% YTD! Large caps mixed with IBB down a tad 0.29%;leaders are BIIB,BMY,RHHBY NASDAQ-100 at record high; QQQ up 0.8% to $195.64. Gilead Sciences (GILD) a big loser on earnings...
by Raynovich Rod | Oct 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/22. Some follow through in biotech rally but sold off mirroring the NASDAQ about 2p,Maybe BREXIT related but we’ll see later this week after many earnings reports. Large caps have been leading and although the IBB was up 1.66% it sold off from $107...
by Raynovich Rod | Oct 15, 2019 | Biopharmaceuticals, Macro
Update-1 Large caps were mixed but our top picks are doing well: ABBV,BMY,MRK,RHHBY. But bad news from JNJ and BA may have curbed buyer’s sentiment. United Health (UNH) off Mondays lows of $220 to $245. In summary it looks like a good time fo adding larger cap...
by Raynovich Rod | Oct 10, 2019 | Biopharmaceuticals
Update-2 10/13…Biotech IPOs Remain Weak-Recent rally was weak for small cap biotechs Vir Biotechnology (VIR): A clinical stage immunology and infectious disease Company focused on new therapies for hepatitis (HBV), Influenza A, HIV and TB went public on Friday....
